Phase II Study of Nivolumab, Ipilimumab (checkpoint inhibitors),Platinum Combination Chemotherapy for Treatment-naive Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases (NIke Study) - LOGIK2004(NIke Study)

Okamoto Isamu0 个研究点目标入组 30 人开始时间: 2021年5月11日最近更新: 2023年10月17日

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•1) Patients with non-small cell lung cancer (NSCLC) confirmed by histological or cytological diagnosis*1.
•2) The clinical stage corresponds to any of the following (1) to (3).
•(1) Stage IV
•(2) Postoperative recurrence.
•(3) Recurrence more than 168 days (24 weeks) after the last radical body radiotherapy.
•3) No history of systemic drug therapy for NSCLC.
•4) For non-squamous cell carcinoma, EGFR mutation is negative. (For squamous cell carcinoma, EGFR mutation analysis is not required)
•5) ALK translocation, ROS1 translocation, BRAF (V600E) mutation, MET exon 14 skipping mutation, RET translocation, NTRK translocation are negative or unknown.
•6) Patients aged 20 years or older at the time of consent.
•7) ECOG performance status 0 or 1.
•8) Patients with at least one cerebral metastasis that is at least 5 mm and twice the head MRI slice thickness, that is symptomatic or asymptomatic and does not require urgent local therapy such as radiation or surgical resection at the time of enrollment. Patients with no history of radiation therapy or surgery. No restrictions on the administration period or dose of steroids as anti-edema therapy for brain metastases.
•9) Patients may or may not have measurable lesions other than brain metastases.
•10) No treatments prior to registration as follows.
•If any prior treatment has been performed, the prescribed period has passed since the end (allowed if it is the same day of the week as the registration date) of the treatment.
•(1) More than 7 days after palliative radiation for non- central nerve metastases
•(2) More than 7days after drainage of pleural or pericardial or abdominal drainage
•(3) More than 7 days after surgery with general anesthesia
•11)No concurrent auto-immune disease or no history of chronic or recurrent auto-immune disease.
•However, controllable auto-immune disease with appropriate treatment is allowed.
•12) Adequate organ function
•(1)Neutrophil count >= 1,500/mm3
•(2)Hemoglobin >=9.0 g/dL
•(3)Platelet count >= 100,000/mm3
•(4)AST, ALT =< 100 IU/L (cases with liver metastases AST, ALT =< 200 IU/L)
•(5)Total bilirubin =< 1.5 mg/dL
•(6)Serum creatinine=< 1.5 mg/dL (non-squamous cell carcinoma: creatinine clearance >= 45mL/min)
•(7) PaO2 >= 60 torr or SpO2 >= 90%
•13) Written informed consent.

排除标准

•1) Active multiple primary cancers.
•2) Local or systemic active infections that require surgical intervention, such as drainage.
•3) Active hepatitis B and active hepatitis C.
•4) Obvious interstitial lung disease on chest CT at enrollment.
•5) Continuous systemic administration of steroids at doses higher than 10 mg / day in terms of prednisolone, or immunosuppressive drugs, for other than anti-edema therapy for brain metastases.
•6) Has serious complications.
•-Brain infarction within a year.
•-Frequent transient ischemic attacks.
•-Symptomatic congestive heart failure, unstable angina, or a history of myocardial infarction within a year.
•-Clinically serious arrhythmia on the electrocardiogram.
•-Gastrointestinal perforation, fistula, diverticulitis within a year.
•-Uncontrollable peptic ulcer.
•7) Diabetes mellitus uncontrollable with the appropriate treatment.
•8) Grade 2 or higher peripheral neuropathy in squamous cell carcinoma.
•9) Hypersensitivity to the ingredients / additives of carboplatin, pemetrexed, paclitaxel, nivolumab, and ipilimumab.
•10) Psychological disorder difficult to participate in this clinical study.
•11) During pregnancy or during lactation.
•12) Other cases that the doctor considers inappropriate

研究者

发起方

Okamoto Isamu

相似试验

进行中（未招募）

1 期

Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

EUCTR2016-001928-54-DKBristol-Myers Squibb International Corporation489

进行中（未招募）

1 期

Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code: 10036909Term: Prostate cancer metastatic Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104

CTIS2022-502909-15-00477

进行中（未招募）

1 期

Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-001928-54-DEBristol-Myers Squibb International Corporation489

进行中（未招募）

1 期

A Study to Evaluate Preliminary Efficacy of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

EUCTR2016-001928-54-ESBristol-Myers Squibb International Corporation495

进行中（未招募）

1 期

Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men, with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-001928-54-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO497